Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...

Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the ...

Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...

BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...

President Trump’s self-branded attempt to cut drug prices, TrumpRx, is set to launch within weeks, offering a novel pathway ...

The collaboration will leverage Abalone Bio’s Functional Antibody Selection Technology platform for an undisclosed ...

With Johnson & Johnson’s participation, 15 of 17 companies contacted by the administration over the summer have now signed on ...

MIT researchers are now turning the prolific Boltz series of models into a software company that promotes open science for AI-guided therapeutics.

Parabilis Medicines raised $305 million in a Series F round led by RA Capital, Fidelity and Janus Henderson, with crossover ...

Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...

Madrigal Pharmaceuticals (MDGL) stock is in focus as the company licenses Pfizer’s (PFE) experimental MASH therapy ervogastat. Read more here.